Overall, our results revealed the mechanism by which HOXA5 acts as an important factor in the acquisition of tamoxifen resistance and enhancement of breast cancer aggressiveness and implied that modulation of HOXA5 expression and its related downstream pathways can demonstrate noteworthy benefits for patients experiencing drug resistance and disease recurrence. The gene discussed is HOXA5; the disease is breast carcinoma.